Now I have sufficient context. Let me write the final consolidated review.

---

## Summary

This paper proposes an end-to-end framework for multi-view diabetic retinopathy (DR) grading that generates lesion proposals internally (GALP) without requiring external lesion annotations, and fuses them across views via a lesion-expert guided routing module (LGRF). The core idea is that grade-conditioned CAMs from auxiliary classifiers can serve as surrogates for costly expert annotations. Experiments on two multi-view datasets (MFIDDR, DRTiD) show that the method matches or exceeds the performance of several externally informed baselines.

## Strengths

- **Competitive performance without external annotations on DRTiD (Table 3):** The method achieves 76.0% accuracy, outperforming all prior methods including those that rely on external cues such as vessel masks (CVSA, 74.7%) and optic disc/macula coordinates (CrossFiT, 75.6%). This is the strongest evidence that the self-derived proposals can substitute for expert annotations, and it is not confounded by backbone differences since the DRTiD comparisons use a fundus-pretrained backbone consistent with the baseline protocol.

- **Ablation confirms modular contributions (Table 4):** Removing GALP drops accuracy by 1.2 points, removing LGRF drops it by 1.6 points, and removing the expert pool drops it by 1.3 points. These degradations are consistent across multiple metrics (Acc, Spe, Kappa, F1), establishing that each proposed component provides a non-redundant benefit.

- **Well-motivated architectural design:** The paper identifies a genuine problem — end-to-end pipelines under-represent small lesions due to spatial compression — and proposes a coherent solution that generates lesion-level cues from within the network. The use of stage-wise auxiliary classifiers, CAM-based proposal selection, and MoE-based cross-view fusion forms a technically sound pipeline.

- **Hyperparameter analysis (Figure 3) provides empirical justification** for key design choices (retention ratio α=0.5, K2=2 experts, M=6 total experts), showing clear performance peaks at the chosen settings.

## Weaknesses

### Major

- **Backbone confound undermines the MFIDDR comparison (Table 1).** The proposed method uses Swin-B, while most baselines use weaker backbones (ResNet50, VGG19, or earlier CNN-transformer hybrids). Even the weakest ablation variant (w/o LGRF, at 82.3%) surpasses every end-to-end baseline (best: ETMC at 81.5%). The 0.8% gap between the simplest variant and the best end-to-end baseline is plausibly backbone-driven. Because the paper does not re-implement any top baseline with Swin-B, the reader cannot determine how much of the reported gain comes from the proposed modules versus the stronger backbone. This does not invalidate the core contribution, but it substantially weakens the SOTA claim on MFIDDR. The DRTiD results (Table 3) are less affected by this issue because the backbone initialization follows the same protocol as the baselines.

- **The claim that GALP proposals capture actual lesions is unsubstantiated.** The paper interprets the Top-K CAM regions as "lesion proposals" (microaneurysms, exudates, etc.) but provides no qualitative validation — no heatmap overlays on fundus images, no comparison with the available lesion segmentation masks on MFIDDR, and no lesion-level metrics. The proposals could highlight any grade-discriminative pattern (e.g., vessel density, image artifacts, or non-anatomical features). This weakens the mechanistic story and the interpretability claim. The core contribution (good grading performance) stands regardless, but the paper would be substantially stronger with this evidence.

### Minor

- **Ablation baselines are not maximally informative.** The "w/o LGRF" variant simply concatenates lesion proposals with cross-view tokens, which is a weak baseline. While the "w/o Experts" variant (plain cross-attention) is a reasonable baseline for the MoE design, the paper does not report whether the expert pool provides meaningful diversity (e.g., by visualizing expert specialization or analyzing expert utilization patterns). The load-balancing loss is mentioned but its empirical impact on expert utilization is not reported.

- **Grade 1 (mild DR) performance is weaker than several baselines.** On MFIDDR (Table 2), the lesion-free variant achieves Grade 1 F1=69.7%, lower than WGLIN (71.4%) and SMVDR-M (71.7%). No explanation is given for this gap. Since mild DR is the most challenging early-stage diagnosis, this is a practically relevant weakness.

- **No lesion-level evaluation.** The paper claims improved "micro-lesion sensitivity" but all metrics are at the grading level. While grading accuracy is the primary endpoint, the claim about lesion sensitivity would benefit from direct lesion detection metrics.

### Trivial

- None.

## Nice-to-Haves

- Re-implementing at least one strong baseline (e.g., CVSA or SMVDR-M) with Swin-B would cleanly isolate the contribution of the proposed modules from the backbone.
- Qualitative visualizations comparing GALP proposals with ground-truth lesion masks (available on MFIDDR) would significantly strengthen the interpretability claim.
- Reporting statistical significance (e.g., confidence intervals over multiple seeds) would help assess whether the ~1% ablation margins are reliable.

## Removed Points

These points are flagged to be removed, treat them with caution:

- **224×224 resolution concern:** The harsh critic claimed that 224×224 is "extremely low resolution" for microaneurysm detection. However, the paper explicitly states it follows prior work on the MFIDDR benchmark (line "Following prior work on this benchmark, we resize each image to 224×224"). This is a dataset convention, not the paper's choice. **Removed.**

- **"The gap of ~1–2% is entirely attributable to backbone strength":** This is an overstatement. The weakest ablation variant (w/o LGRF, 82.3%) still includes GALP, experts, and cross-attention — it is not a pure-backbone baseline. The gap between the weakest variant and the best end-to-end baseline (ETMC, 81.5%) is 0.8%, not 1–2%. The claim of "entirely attributable" is speculative. **Weakened to Major (above) with the correct framing.**

- **Missing related works / missing appendix / missing proofs:** These are either parser artifacts or unverifiable. **Removed per rules.**

- **Generic sweep concerns** (e.g., "could the metric be measuring a proxy?", "are confounders controlled?") that lack specific anchors in the paper text. **Removed.**

- **Formatting/style nitpicks** about Figure 2 being "difficult to parse" and "captions repetitive." These are presentation preferences, not substantive flaws. **Removed.**

## Novel Insights

None beyond the paper's own contributions. The reviews do not surface a perspective that meaningfully reinterprets the paper's results or unifies them with a broader framework.

## Suggestions

1. **Address the backbone confound** by re-implementing one strong baseline (e.g., CVSA or SMVDR-M) with Swin-B on MFIDDR. This would directly quantify how much of the reported gain is from the proposed modules versus the backbone.
2. **Add qualitative validation of GALP proposals** — overlay the GEMs on original fundus images and compare with available lesion segmentation masks. Report a simple proposal-level recall metric (e.g., what fraction of ground-truth lesion pixels fall within the Top-K proposals).
3. **Report standard deviations** over 3–5 random seeds for the main results and ablations. The ~1.2–1.6% ablation margins could be meaningful only if they exceed run-to-run variance.
4. **Discuss the Grade 1 weakness** — is this because mild DR has sparse lesions that the proposal mechanism struggles with, or because the CAMs are less reliable at this stage?

## Score and Decision

**Calibration report:**

**Round 1 — Bracketing:**
| Path | Avg Score | Round | Comparison |
|------|-----------|-------|------------|
| EjIKerYk1O (aircraft multi-view) | 2.33 | R1 | Unrelated domain, clearly rejected. Paper is much stronger. |
| hrXt6Fdl2P (free-viewpoint video) | 2.60 | R1 | Unrelated domain, rejected. Paper is much stronger. |
| M3kBtqpys5 (trusted multi-view classif.) | 6.25 | R1 | Similar multi-view topic, accepted. The current paper has comparable methodology but weaker evidence for its core claim. |
| NJxCpMt0sf (medical MoE) | 5.75 | R1 | Very similar framing (medical MoE, multi-modal fusion). The current paper is cleaner in presentation and more focused. |
| t1J2CnDFwj (multi-view alignment) | 5.75 | R1 | Similar multi-view classification. Current paper is comparable in quality but has a more applied medical focus. |
| RqJ0px8osW (image fusion) | 6.80 | R1 | Different domain but comparable depth. The current paper has a more significant backbone confound. |
| 3b9SKkRAKw (LeFusion) | 8.00 | R1 | Top-tier paper with extensive validation. Current paper is substantially weaker in evidence quality. |

**Round 1 bracket:** 5.0 – 7.0

**Round 2 — Narrowing:**
| Path | Avg Score | Round | Comparison |
|------|-----------|-------|------------|
| yVJd8lKyVX (HSQ MoE) | 6.00 | R2 | MoE for multi-label. Similar backbone comparison issues. Current paper has a more novel application (self-derived proposals) but weaker evidence for its core claim. |
| QG31By6S6w (Malenia lesion seg.) | 6.25 | R2 | Lesion segmentation with strong validation. Current paper lacks the lesion-level validation this paper provides. |
| kcmK2utDhu (MV-Adapter) | 5.80 | R2 | Multi-view generation, rejected. Current paper is more solid in evaluation. |
| GuQeZWbaGr (AnyView) | 5.50 | R2 | Multi-view generation, rejected. Current paper is stronger in methodology. |

**Final score:** 5.5

The paper sits slightly below the 5.75–6.25 range of accepted multi-view/medical papers because the backbone confound on MFIDDR and the lack of qualitative lesion validation weaken the evidence for the core claims. The DRTiD results are convincing and the method is well-designed, but the MFIDDR comparison does not adequately isolate the contribution of the proposed modules from the backbone advantage. The paper is a borderline accept — the ideas are promising and the contribution is real, but the empirical evidence needs strengthening.

MY FINAL SCORE: <score>5.5</score>
MY FINAL DECISION: <decision>Reject</decision>